Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Ticker
$MLYS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
51
ISIN
US6031701013
Website
MLYS Metrics
BasicAdvanced
$935M
-
-$3.73
-0.18
-
Price and volume
Market cap
$935M
Beta
-0.18
52-week high
$18.38
52-week low
$8.69
Average daily volume
794K
Financial strength
Current ratio
26.483
Quick ratio
25.626
Profitability
EBITDA (TTM)
-201.438
Management effectiveness
Return on assets (TTM)
-35.87%
Return on equity (TTM)
-56.31%
Valuation
Price to book
2.72
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-3.766
Free cash flow yield (TTM)
-26.55%
Free cash flow per share (TTM)
-380.79%
Growth
Earnings per share change (TTM)
69.12%
Bulls say / Bears say
Lorundrostat demonstrated significant efficacy in the Launch-HTN trial, achieving a 16.9 mmHg reduction in systolic blood pressure at week 6, with a 9.1 mmHg placebo-adjusted reduction (p<0.0001), and further improvements at week 12 with a 19.0 mmHg reduction. (stocktitan.net)
The Advance-HTN trial results were presented at the American College of Cardiology’s ACC.25 meeting and published in the New England Journal of Medicine, highlighting lorundrostat's potential as a transformative treatment for uncontrolled or resistant hypertension. (nasdaq.com)
Mineralys completed a public equity financing of approximately $201.2 million in March 2025, bolstering its cash reserves to $343.0 million as of March 31, 2025, expected to fund operations into 2027. (nasdaq.com)
Mineralys reported a net loss of $42.2 million for Q1 2025, an increase from $31.5 million in Q1 2024, primarily due to rising research and development expenses. (nasdaq.com)
The company launched a $250 million public offering of common stock in March 2025, which could lead to shareholder dilution. (investing.com)
Pomerantz LLP announced an investigation into claims on behalf of investors of Mineralys Therapeutics, raising concerns about potential securities fraud or other unlawful business practices. (prnewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MLYS News
AllArticlesVideos
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
GlobeNewsWire·3 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewsWire·2 months ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $935M as of July 18, 2025.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of July 18, 2025.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of -0.18. This means that it has an inverse relation to market volatility.